The stock has a 36-month beta value of 0.88. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JAGX is 13.59M, and at present, short sellers hold a 7.01% of that float. On March 18, 2025, the average trading volume of JAGX was 409.93K shares.
JAGX) stock’s latest price update
The stock of Jaguar Health Inc (NASDAQ: JAGX) has decreased by -30.68 when compared to last closing price of 0.47. Despite this, the company has experienced a -31.77% fall in its stock price over the last five trading sessions. accessnewswire.com reported 2025-03-18 that Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock (“Common Stock”), at an exchange ratio of 1-for-25, on Monday, March 24, 2025 (the “Effective Date”) in order to support the Company’s compliance with Nasdaq’s listing standards. The Company’s Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol “JAGX”.
JAGX’s Market Performance
JAGX’s stock has fallen by -31.77% in the past week, with a monthly drop of -63.87% and a quarterly drop of -66.66%. The volatility ratio for the week is 12.90% while the volatility levels for the last 30 days are 11.44% for Jaguar Health Inc The simple moving average for the past 20 days is -46.61% for JAGX’s stock, with a -78.84% simple moving average for the past 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -58.98% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.49% of loss for the given period.
Volatility was left at 11.44%, however, over the last 30 days, the volatility rate increased by 12.90%, as shares sank -67.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -70.17% lower at present.
During the last 5 trading sessions, JAGX fell by -31.77%, which changed the moving average for the period of 200-days by -92.54% in comparison to the 20-day moving average, which settled at $0.6089. In addition, Jaguar Health Inc saw -67.81% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.85 for the present operating margin
- 0.69 for the gross margin
The net margin for Jaguar Health Inc stands at -3.6. The total capital return value is set at -0.77. Equity return is now at value -432.40, with -72.69 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at -0.85. The debt to equity ratio resting at 2.52. The interest coverage ratio of the stock is -34.76.
Currently, EBITDA for the company is -33.13 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 2.52. The receivables turnover for the company is 8.02for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
To sum up, Jaguar Health Inc (JAGX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
